Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 34Carcinoma, Non-Small-Cell Lung 22Carcinoma, Renal Cell 20Neoplasm Metastasis 13Carcinoma, Hepatocellular 10Brain Neoplasms 8Lung Neoplasms 7Skin Neoplasms 6Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Kidney Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Ovarian Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Sarcoma 3Recurrence 3Mesothelioma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3

Interventions

Specimen Handling 4Radiotherapy 4Radiation 4Nivolumab 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Doxorubicin 3CTLA-4 Antigen 3Biopsy 3talimogene laherparepvec 1peposertib 1pazopanib 1liposomal doxorubicin 1fludarabine 1cabozantinib 1aldesleukin 1X-Rays 1Trabectedin 1Ifosfamide 1Histamine H2 Antagonists 1Famotidine 1Dactinomycin 1Cyclophosphamide 1BO-112 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × Ipilimumab × 90 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05836571 2026-04-21

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

NCT03307616 2026-03-05

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡